drugset / Trial / NCT05271604
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Timeline
- Start
- 2022-12-13
- Primary completion
- 2025-09-22
- Completion
- 2025-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BA3021 | Unknown | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Evalstotug | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |